BioNTech Results Presentation Deck
2021 Key Highlights of Progress Towards Vision
COVID-19 VACCINE ~2.6 Bn
doses delivered
GLOBAL LEADERSHIP
in 2021
7
e
Multiple randomized
Phase 2 trials
2 Fix Vac programs
2 iNeST programs
1 Bispecific Immunomodulator
●
to
DROVE ADVANCEMENT IN ONCOLOGY
New platforms
entered the clinic
RiboCytokines
RiboMabs
CAR-T cell therapy
NEOSTIM individualized
neoantigen T cell therapy
EXPANDED GLOBAL ORGANIZATION
3,000+ team members
Increased footprint with new offices in
U.S., Europe and Asia
> 165
countries &
territories ¹
●
●
●
>1 Bn
to low- and middle-
income countries ¹
Strategic M&A to complement
existing technologies
Acquired Kite's cell therapy facility in U.S.
Kite asset acquisition expanded personalized
TCR platform
Expanded TCR pipeline with Medigene asset
acquisition and research collaboration
STRONG FINANCIAL PERFORMANCE
€19.0 Bn
Total 2021 Revenues²
1 As of end 2021
2 Estimated figures based on preliminary data shared between Pfizer and BioNTech as further described in our Annual Report on Form 20-F for the year ending December 31, 2021
€39.63
Diluted EPS²
BIONTECHView entire presentation